- The pulmonary and nasal routes have long been
considered a potentially excellent and pain free alternative for the
administration of drugs which currently have to be given via a
needle. The goal of maximising these routes received a recent boost
with the introduction of TouchSprayTM Technology which is capable of
generating precisely controlled aerosols of therapeutically
beneficial drugs. TouchSprayTM Technology's precision control of
aerosols generation will facilitate optimal drug absorption in the
relevant pulmonary and nasal regions.
This innovative technology has been licensed to a new joint
venture company, ODEM, for pulmonary and nasal inhaler applications.
Three companies have joined forces to form ODEM - Bespak, a
leading manufacturer of drug delivery systems and one of the largest
volume suppliers of inhalers; PARI GmbH a market leader in the supply
of nebulisers and The Technology Partnership (TTP), Europe's leading
independent technology development company.
The combination of electronic control, precise droplet size and
low droplet velocity enables TouchSprayTM Technology to deliver
therapeutically beneficial drugs deep into the lungs in a consistent
and efficient manner. TouchSprayTM Technology is suitable for the
treatment of diseases local to the lung (e.g. Asthma and COPD) as
well as for the systemic delivery of compounds, which previously had
to be administered via a needle. Drugs such as insulin for the
treatment of diabetes and other proteins/peptides for the treatment
of cancer, multiple sclerosis, hepatitis C and other specific
conditions could all be administered to the patient via the lung and
in certain cases the nose, using TouchSprayTM Technology.
ODEM has appointed Dr Jonathan Smart as Head of Commercial
Development. He joins ODEM after spending 14 years working for
leading international pharmaceutical companies both in the technical
and commercial areas. Dr Smart will be responsible for the
development of partnerships with leading pharmaceutical an biotech
Commenting on the potential for TouchSprayTM Technology, Jonathan
Smart said: "The systemic delivery of compounds through the lung has
always been seen as an excellent alternative to the invasive
parenteral route. TouchSprayTM Technology has the potential to unlock
this route with its ability to precisely and efficiently deliver
suitable aerosolised drugs deep into the lung. It is an extremely
efficient and innovative method of delivery that will revolutionise
the treatment of certain diseases."
Talking about the scope of ODEM, Gaynor Fryers, Commercial
Director at Bespak, said: "The depth of our experience at Bespak in
device development for the inhalation market and experience in
developing commercially viable devices for full-scale manufacture
will be available to the joint venture as will the invaluable an
complementary expertise of PARI and TTP."
"This combination of expertise and experience, really is
formidable and, when you put that together with a breakthrough such
as TouchSprayTM Technology, it is really a very exciting
Dr Martin Knoch, Managing Director of PARI GmbH, said: "Right now
PARI and TTP are developing an advanced electronic nebuliser system
based on TouchSprayTM Technology. ODEM will receive immediate benefit
from this through early recognition of the new technology an the
market and the experience and knowledge that has already been built
up. PARI look forward to contributing their R & D and market
expertise to this challenging new enterprise."
"As a part of our on-going strategy of creating new technology
based business," commented Dr David Parnell, a director of TTP, "TTP
has invested many man-years of development in TouchSprayTM Technology
and the creation of ODEM will enable a whole generation of drug
delivery devices to be brought to the healthcare market."
Bespak, TTP and PARI will all have equal shares in the new joint
venture, with Gaynor Fryers, Commercial Director at Bespak, David
Parnell, Director at TTP and Martin Knoch, Managing Director at PARI
GmbH becoming directors of ODEM.
Bespak plc ha sits main production facility in King's Lynn and
additional plants in Milton Keynes and the USA. The company is in the
forefront of developing new delivery systems for the pharmaceutical
industry. It has a product range covering metered dose inhalers, dry
powder inhalers, actuator and spacer systems, as well as specialist
components and assemblies for the medical device industry. Bespak
will provide the industrialisation and manufacturing expertise in
high volume automated moulding and assembly for the ODEM products and
certain product development activities.
Bespak UK headquarters are based in Bergen Way, King's Lynn,
Phone +44 (0) 1553 691000
Fax +44 (0) 1553 693728
PARI GmbH is a third-generation family-owned German company that
is run jointly by Dr Zimmermann, who heads up the commercial side of
the business and Dr Martin Knoch who is the company's technical head.
The company specialises in the development, manufacture and sales of
sophisticated nebulisers and compressors that are particularly
applicable to the treatment of seriously ill and home-based patients
who require high dosage of medication. PARI will provide ODEM with
the manufacturing expertise for the atomizing heads of ODEM's
products and play a role in product development.
PARI GmbH headquarters are located in Moosstrasse 9 D-82319
Phone +49 (8151) 279 - 0
Fax +49 (8151) 279 - 101
The Technology Partnership plc (TTP) is Europe's major independent
product development company providing a continuous stream of new
products for the world's largest companies as well as the smallest
and most ambitious TTP develops and supplies systems for both the
manufacturing and testing of pharmaceuticals as well as for drug
discovery and drug delivery. TTP will provide development expertise
for customised atomizing heads and inhaler product design.
TTP is located at Melbourn Science Park, Cambridge Road, Melbourn,
Royston Herts SG8 6EE.
Phone +44 (0) 1763 262626
Fax +44 (0) 1763 261582
ots Originaltext: ODEM Limited
Dr Jonathan Smart
Melbourne Science Park
Cambridge Road, Melbourn
Phone +44 1763 266200
Fax +44 1763 266290
D/A/CH : Pharma, Gesundheit